Hualan Biological Engineering Inc.

002007

CNE000001JN8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
19.04 ^CNY	-0.26%		-0.16%	-13.96%

Apr. 25	Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Hualan Biological Engineering's Profit Rises 38%; Tops EPS, Revenue Estimates	MT

Hualan Biological Engineering Inc. Proposes Final Dividend for 2022

March 30, 2023 at 04:18 pm EDT

Hualan Biological Engineering Inc. proposed Cash dividend/10 shares (tax included): CNY 3.00000000 for the year 2022.

Latest news about Hualan Biological Engineering Inc.

Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Hualan Biological Engineering's Profit Rises 38%; Tops EPS, Revenue Estimates	Apr. 01	MT
Hualan Biological Engineering Inc. Proposes Profit Distribution for 2023	Apr. 01	CI
Hualan Biological Engineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Hualan Biological Engineering Obtains Blood Collection License	Feb. 02	MT
Hualan Biological Engineering Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Hualan Biological Engineering Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Hualan Biological Engineering's Plasma Station Gets Permit to Collect Blood	23-08-16	MT
Hualan Biological Engineering's Unit Gets Nod to Trial Antibody Injection	23-07-07	MT
Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023	23-06-07	CI
Hualan Biological Engineering Obtains Blood Plasma Collection License	23-05-31	MT
Hualan Biological Engineering's Unit Gets Nod for Trial of Tumor Drug	23-05-05	MT
Hualan Biological Engineering Inc. Approves Cash Dividend for 2022	23-04-24	CI
Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Hualan Biological Engineering Inc. Proposes Final Dividend for 2022	23-03-30	CI
Hualan Biological Bacterin Registers Freeze-Dried Human Rabies Vaccine	23-02-01	MT
Hualan Biological Engineering Wins Approval to Build Apheresis Stations	22-12-28	MT
Hualan Biological to Sell Assets to Joint Stock Company for $27 Million	22-11-17	MT
Hualan Biological Engineering Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
China's Sept factory activity set for third straight monthly contraction:Reuters poll	22-09-29	RE
Hualan Biological Engineering Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Hualan Biological Engineering Inc. Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022	22-06-08	CI
Hualan Biological Engineering Inc. Approves Cash Dividend for the Year 2021	22-04-29	CI
Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Hualan Biological Engineering Inc. Proposes Final Cash Dividend for the Year 2021	22-03-30	CI

Chart Hualan Biological Engineering Inc.

Duration

Period

Chart Hualan Biological Engineering Inc.

More charts

Hualan Biological Engineering, Inc. specializes in the research, development, manufacturing and marketing of biological and sanguine products and vaccines. The group's products include immunoglobulin for intravenous injections, lyophilized surgical fibrin, lyophilized thrombin for external use, vaccines against cold, etc.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hualan Biological Engineering Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.04 CNY

Average target price

25.78 CNY

Spread / Average Target

+35.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
HUALAN BIOLOGICAL ENGINEERING INC.	-13.96%	4.82B
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
INCYTE CORPORATION	-18.49%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B

Biopharmaceuticals